Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1949 1
1957 1
1962 1
1967 1
1968 1
1970 1
1971 3
1972 5
1973 3
1974 3
1975 4
1976 7
1977 7
1978 8
1979 8
1980 13
1981 8
1982 10
1983 16
1984 5
1985 11
1986 13
1987 9
1988 11
1989 9
1990 19
1991 8
1992 15
1993 14
1994 20
1995 11
1996 19
1997 17
1998 21
1999 17
2000 13
2001 15
2002 15
2003 13
2004 14
2005 23
2006 15
2007 12
2008 19
2009 20
2010 19
2011 19
2012 19
2013 17
2014 21
2015 22
2016 25
2017 32
2018 19
2019 17
2020 12
2021 18
2022 14
Text availability
Article attribute
Article type
Publication date

Search Results

688 results
Results by year
Filters applied: . Clear all
Page 1
Epigenetic therapy in immune-oncology.
Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Jones PA, et al. Nat Rev Cancer. 2019 Mar;19(3):151-161. doi: 10.1038/s41568-019-0109-9. Nat Rev Cancer. 2019. PMID: 30723290 Review.
Epigenetic Determinants of Cancer.
Baylin SB, Jones PA. Baylin SB, et al. Among authors: jones pa. Cold Spring Harb Perspect Biol. 2016 Sep 1;8(9):a019505. doi: 10.1101/cshperspect.a019505. Cold Spring Harb Perspect Biol. 2016. PMID: 27194046 Free PMC article. Review.
Targeting the cancer epigenome for therapy.
Jones PA, Issa JP, Baylin S. Jones PA, et al. Nat Rev Genet. 2016 Sep 15;17(10):630-41. doi: 10.1038/nrg.2016.93. Nat Rev Genet. 2016. PMID: 27629931 Review.
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, Wong K, Pathuri S, Briand J, Steidel M, Chapman P, Groy A, Wiseman AK, McHugh CF, Campobasso N, Graves AP, Fairweather E, Werner T, Raoof A, Butlin RJ, Rueda L, Horton JR, Fosbenner DT, Zhang C, Handler JL, Muliaditan M, Mebrahtu M, Jaworski JP, McNulty DE, Burt C, Eberl HC, Taylor AN, Ho T, Merrihew S, Foley SW, Rutkowska A, Li M, Romeril SP, Goldberg K, Zhang X, Kershaw CS, Bantscheff M, Jurewicz AJ, Minthorn E, Grandi P, Patel M, Benowitz AB, Mohammad HP, Gilmartin AG, Prinjha RK, Ogilvie D, Carpenter C, Heerding D, Baylin SB, Jones PA, Cheng X, King BW, Luengo JI, Jordan AM, Waddell I, Kruger RG, McCabe MT. Pappalardi MB, et al. Among authors: jones pa. Nat Cancer. 2021 Oct;2(10):1002-1017. Epub 2021 Sep 27. Nat Cancer. 2021. PMID: 34790902 Free PMC article.
Epigenetics in cancer.
Sharma S, Kelly TK, Jones PA. Sharma S, et al. Among authors: jones pa. Carcinogenesis. 2010 Jan;31(1):27-36. doi: 10.1093/carcin/bgp220. Epub 2009 Sep 13. Carcinogenesis. 2010. PMID: 19752007 Free PMC article. Review.
688 results